Actinogen Medical Limited ACN 086 778 476 Suite 901, Level 9, 109 Pitt Street, Sydney NSW 2000 +61 2 8964 7401 | actinogen.com.au 1 ASX ANNOUNCEMENT Xanamem oral presentation at the 6th International Conference on Cognitive and Behavioral Neurosciences by Actinogen’s Chief Medical Officer Dr...
ACW CMO international Xanamem presentation
Filed with ASX · · 26 pages · English
Release
Actinogen Medical Limited on 6ix
In the deck
Story so far
- Xanamem depression trial published in British J Psychiatry
- Actinogen achieves agreement with the FDA in a Type C meeting on the manufacturing, clinical and nonclinical activities required for a future US marketing approval of Xanamem for Alzheimer’s disease
- Actinogen trial using intended commercial Xanamem tablet formulation confirms target exposures in fed and fasted states
Earlier from Actinogen Medical
- Application for quotation of securities - ACW
- Response to ASX Price Query
- ACW unlisted options fully underwritten
- Proposed issue of securities - ACW
- Appendix 3Y-Dr George Morstyn
Later from Actinogen Medical
- Appendix 3Y-Dr Geoffrey Brooke
- Notification of cessation of securities - ACW
- ACW Alzheimers pivotal trial completes last patient visit
- Options underwriting cleansing notice
- Underwriting of unlisted options completed
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical